U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07246564) titled 'Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis' on Nov. 17.

Brief Summary: The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Myasthenia Gravis

Intervention: DRUG: Rozanolixizumab

Subcutaneous infusion

Recruitment Status: NOT_YET_RECRUITING

Sponsor: UCB Biopharma SRL

Disclaimer: Curated by HT Syndication....